Alexion Pharmaceuticals to create 200 new jobs in Dublin

Alexion Pharmaceuticals to create 200 new jobs in Dublin


Reading Time: < 1 minute

Alexion Pharmaceuticals has announced expansion plans which could create up to 200 new jobs in Dublin.

The pharma company intends to significantly expand its operations in Ireland, constructing the Company’s first ever biologics manufacturing facility outside the United States.

This €450 million, four-year project, which will be constructed at Alexion’s College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, which will bring Alexion’s total workforce in Ireland to almost 500 employees.

Julie O’Neill, EVP Global Operations says “This project further underscores our commitment to Ireland and is enabled by our ability to recruit highly competent and professional personnel to support the production and distribution of our medicine, Soliris, and our strong pipeline of biologics medicines.”

“Alexion has a unique mission to develop life-transforming therapies for patients with severe and life-threatening ultra-rare disorders. We are already serving the very few patients in Ireland suffering from two very rare and devastating diseases; with this major expansion, our Irish operations, comprising biologics manufacturing, vial fill-finish and global supply chain, will be at the forefront of this vital work globally.” she added.

Since coming to Ireland in 2013, Alexion has invested €130 million in two facilities – a vial fill-finish facility in Athlone and a Global Supply Chain facility at College Park.

Phase 1 of the College Park facility, comprising Global Supply Chain HQ, laboratories, packaging and warehousing operations is expected to be operational by year-end.

Approximately 560 construction workers are involved in the development of the current Athlone and College Park projects, and the planned expansion of College Park will also create over 800 construction jobs.

If granted permission, Phase 2 of College Park is expected to take four years to complete.